PMID- 10629557
OWN - NLM
STAT- MEDLINE
DCOM- 20000214
LR  - 20210102
IS  - 0022-3417 (Print)
IS  - 0022-3417 (Linking)
VI  - 189
IP  - 4
DP  - 1999 Dec
TI  - Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with 
      heavy infiltration of T cells in human malignant melanoma.
PG  - 552-8
AB  - Human malignant melanoma (MM) is a highly aggressive tumour which is particularly 
      prone to specific local immune responses. To determine the microanatomical 
      location and the species of chemokines possibly involved in the intricate control 
      of cell migration and positioning of immune effector cells in primary and 
      metastatic MM lesions, the expression of those chemokines with lymphocyte and/or 
      macrophage chemoattractant properties was analysed by in situ hybridization. 
      GROalpha (growth-related oncogene) and IL-8 (interleukin 8) were expressed at low 
      levels by single melanoma cells, adjacent keratinocytes, and infiltrating 
      leukocytes. In contrast, the lymphocyte-specific chemokine Mig (monokine induced 
      by interferon-gamma) was strongly expressed by mononuclear cells (mainly 
      macrophages) infiltrating the tumour margin in primary MM lesions, whereas 
      expression was less intense in MM metastasis. IP-10 (interferon-gamma inducible 
      protein 10) was expressed in the same loci at lower intensity. Marked 
      infiltration of T cells was exclusively detected in those areas which exhibited 
      strong Mig expression, whereas areas in the vicinity of tumour cells devoid of 
      Mig expression were not infiltrated. In contrast to Mig, expression of MCP-1 
      (macrophage chemotactic protein-1) was weaker and mainly detected in lesional 
      basal keratinocytes, occasionally at sites of macrophage infiltration, as well as 
      in single melanoma cells. MIP-1alpha (macrophage inflammatory protein 1alpha) 
      showed similar, albeit weaker expression compared with MCP-1. Other chemokines 
      relevant for the recruitment of monocytes and lymphocytes, such as RANTES 
      (regulated on activation, normal T cells expressed and secreted) and MIP-1beta, 
      were barely detectable. In summary, the chemokine expression profiles support the 
      notion that particularly in heavily infiltrated primary MM lesions, Mig and to a 
      lesser extent IP-10 are important mediators of an IFN-gamma-dependent pathway. 
      Due to their lymphoattractant properties and the known inhibitory effects on the 
      tumour vasculature, both chemokines may be critical for the control of local 
      melanoma tumour growth.
CI  - Copyright 1999 John Wiley & Sons, Ltd.
FAU - Kunz, M
AU  - Kunz M
AD  - Department of Dermatology, University of Wurzburg, Wurzburg, Germany.
FAU - Toksoy, A
AU  - Toksoy A
FAU - Goebeler, M
AU  - Goebeler M
FAU - Engelhardt, E
AU  - Engelhardt E
FAU - Brocker, E
AU  - Brocker E
FAU - Gillitzer, R
AU  - Gillitzer R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pathol
JT  - The Journal of pathology
JID - 0204634
RN  - 0 (CXC chemokine Mig)
RN  - 0 (Chemokine CXCL10)
RN  - 0 (Chemokine CXCL9)
RN  - 0 (Chemokines, CXC)
RN  - 0 (Interleukin-1)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
CIN - J Pathol. 2000 Nov;192(3):413-5. PMID: 11054726
MH  - Chemokine CXCL10
MH  - Chemokine CXCL9
MH  - Chemokines, CXC/genetics/*metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization
MH  - Interferon-gamma/pharmacology
MH  - Interleukin-1/pharmacology
MH  - Lymphocytes, Tumor-Infiltrating/*pathology
MH  - Macrophages/metabolism
MH  - Melanoma/*immunology/secondary
MH  - Neoplasm Proteins/genetics/*metabolism
MH  - RNA, Messenger/analysis
MH  - Skin Neoplasms/*immunology/secondary
MH  - Tumor Cells, Cultured/immunology
MH  - Tumor Necrosis Factor-alpha/pharmacology
EDAT- 2000/01/12 09:00
MHDA- 2000/02/19 09:00
CRDT- 2000/01/12 09:00
PHST- 2000/01/12 09:00 [pubmed]
PHST- 2000/02/19 09:00 [medline]
PHST- 2000/01/12 09:00 [entrez]
AID - 10.1002/(SICI)1096-9896(199912)189:4<552::AID-PATH469>3.0.CO;2-I [pii]
AID - 10.1002/(SICI)1096-9896(199912)189:4<552::AID-PATH469>3.0.CO;2-I [doi]
PST - ppublish
SO  - J Pathol. 1999 Dec;189(4):552-8. doi: 
      10.1002/(SICI)1096-9896(199912)189:4<552::AID-PATH469>3.0.CO;2-I.